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Abstract
Homeostatic bone remodelling becomes disturbed in a variety of pathologic conditions that affect the skeleton,
including inflammatory diseases. Rheumatoid arthritis is the prototype of an inflammatory arthritis characterised by
chronic inflammation, progressive cartilage destruction and focal bone erosions and is a prime example for a
disease with disturbed bone homeostasis. The inflammatory milieu favours the recruitment and activation of
osteoclasts, which have been found to be the cells that are primarily responsible for bone erosions in many animal
models of inflammatory arthritis. Among the inflammatory modulators, members of the transforming growth factor
(TGF)-β super family are shown to be important regulators in osteoclastogenesis with Smad-mediated signalling
being crucial for inducing osteoclast differentiation. These findings have opened a new field for exploring
mechanisms of osteoclast differentiation under inflammatory conditions. Recent studies have shown that the TGF-β
superfamily members TGF-β1, myostatin and activin A directly regulate osteoclast differentiation through
mechanisms that depend on the RANKL–RANK interplay. These growth factors transduce their signals through type
I and II receptor serine/threonine kinases, thereby activating the Smad pathway. In this review, we describe the
impact of inflammation-induced Smad signalling in osteoclast development and subsequently bone erosion in
rheumatoid arthritis.
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Background
Sustained bone remodelling is important for healthy con-
servation of mobility and structure of the skeleton, in
which bone matrix is constantly resorbed by osteoclasts
and subsequently replaced with new bone by osteoblasts.
Thus, bone remodelling requires the coordinated actions
of the bone-resorbing osteoclasts and the bone-forming
osteoblasts [1, 2].
An imbalance of this homeostatic process through a
perturbation by inflammatory cytokines, growth factors
and hormones can result in skeletal abnormalities, such
as osteoporosis, osteopetrosis or rheumatoid arthritis
(RA) [3, 4]. In RA, a variety of pathologic conditions
affect the skeleton, in which altered levels of proinflam-
matory cytokines stimulate bone resorption in the in-
flamed joints.
RA is a systemic disorder characterised by chronic in-
flammation, hyperplasia of synovial lining cells and the
deep infiltration of the inflamed and hyperplastic syno-
vium into the joint structures. Pathology starts with a
painful inflammation of the synovial tissues, tendon
sheaths and bursae and eventually results in the progres-
sive destruction of the articular cartilage and subchon-
dral bone of the affected joints [5, 6]. Focal bone
erosions occur at the interface between cortical bone
and immigrant pannus tissue and at the subchondral
bone where the pannus invades the bone marrow [7].
Arthritic bone erosions are mediated by osteoclast pre-
cursors and mature osteoclasts [8].
Besides bone erosion, extensive inflammation is
present during the progression of RA and inflammatory
mediators released by cells of the invasive pannus are in-
volved in the inflammatory process in RA, resulting in
destruction of physiological tissue barriers. Many of the
cytokines and growth factors implicated in the inflam-
matory process have also been demonstrated to impact
directly or indirectly on osteoblast and/or osteoclast dif-
ferentiation and function [9, 10]. Here, we want to focus
on several members of the transforming growth factor
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(TGF)-β super family that influence osteoclast develop-
ment and bone destruction in arthritis.
RANKL-mediated osteoclast development and
activation
Cells of the monocyte/macrophage lineage, which are lo-
cated in the synovial tissue of inflamed joints in RA,
serve as potential osteoclast precursors and drive osteo-
clast formation by specific molecular signal induction
[11, 12]. Osteoclasts differentiate from these progenitors
in the presence of macrophage colony stimulating factor
(M-CSF; also called CSF-1) and receptor activator of nu-
clear factor κB ligand (RANKL). Osteoblasts secrete the
cytokines M-CSF as well as RANKL, which is also
expressed by T lymphocytes, osteoclasts and fibroblast-
like synovial cells as part of the pannus [11, 13]. M-CSF
binds to its receptor FMS on the surface of premature
osteoclasts and activates signalling pathways essential for
proliferation and survival of osteoclast precursors [12].
Subsequent binding of soluble or membrane bound
RANKL to the receptor activator of nuclear factor κB
(RANK) on the cell surface of osteoclast precursors and
mature osteoclasts leads to the formation, activation and
survival of mature osteoclasts. The action of RANKL is
regulated by osteoprotegerin (OPG), which is secreted
by osteoblasts and impairs the binding of RANKL on its
specific receptor RANK by binding of soluble RANKL
as a decoy receptor [14–17].
Binding of RANKL to RANK leads to the recruitment
of the adaptor protein TNF receptor-associated factor 6
(TRAF6), which results in a trimeric complex formation
of TRAF6, TAB2, TAB1 and TGF-beta-activated kinase 1
(TAK1) [18, 19]. TAK1 is activated, which subsequently
leads to the activation of downstream signalling path-
ways such as NF-κB, p38 mitogen-activated protein kin-
ase (p38 MAPK) and c-Jun N-terminal kinase 1 (JNK1)
[12, 18, 20] and the induction of c-fos/c-jun hetero- and
homodimeric transcription factors (AP-1) [12].
However, the master transcription factor of osteoclast
differentiation is nuclear factor of activated T-cells cyto-
plasmic 1 (NFATc1), which is stimulated by RANKL via
TRAF6, c-Fos and NF-κB signalling as well as through the
activation of immunoreceptor tyrosine-based activation
motif containing receptors (ITAMs), e.g. FcγR and recruit-
ment of spleen tyrosine kinase (SYK) by the activation of
phospholipase Cγ (PLCγ). Interestingly, NFATc1 can
auto-regulate its expression through binding on its own
promoter through the NFAT-binding side [21]. Activation
and nuclear translocation of NFATc1 is mediated by cal-
cineurin upon RANKL-induced Ca2+ oscillations [12, 18,
20, 22]. Following translocation into the nucleus, NFATc1
together with other transcription factors like AP-1,
microphthalmia-associated transcription factor (MITF),
Fig. 1 Osteoclasts arise from hematopoietic monocyte/macrophage precursors upon interaction of RANKL with its receptor RANK. Both are key regulators
of bone remodelling and essential for the development, activation and survival of osteoclasts. Binding of RANKL to RANK leads to the recruitment of
TRAF6, which activates Akt (survival), NF-κB and the mitogen-activated protein kinases p38, ERK and JNK, resulting in the induction of the transcription
factors c-Jun, c-Fos and NFATc1, all crucial for osteoclast differentiation. As an important signalling cascade promoting the RANKL-induced osteoclastogene-
sis, the Smad signalling pathway, which can be activated by transforming growth factor (TGF)-β family members, including TGF-β, activin and myostatin,
has been identified. By way of example, myostatin signals through the ActRIIB-ALK4/5 heterodimer to activate Smad2/3, which subsequently translocates
directly to the nuclear compartment or binds first to NFATc1 and then translocates into the nucleus, both leading to enhanced expression of several
osteoclast-specific target genes, including NFATc1 itself. Smad-mediated translocation of c-Fos, which has been demonstrated upon TGF-β stimulation
during RANKL-mediated osteoclastogenesis is also indicated in the figure. ECM extracellular matrix, Ub ubiquitin
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PU.1 or CREB induce the expression of various osteoclast-
specific genes, such as those encoding cathepsin K,
tartrate-resistant acid phosphatase (TRAP), calcitonin re-
ceptor, osteoclast-associated receptor (OSCAR) and β3-in-
tegrin [21]. Finally, binding of TRAF6 potentiates the
activation of c-Src/SFK kinase, leading to an activation of
phosphatidylinositol 3 kinase (PI3K), which, in turn, leads
to an activation of protein kinase B (PKB), which has an
anti-apoptotic effect on osteoclasts by inactivation of pro-
apoptotic proteins such as caspase-9 [18, 23].
The activation of mature osteoclasts by RANKL in-
volves the expression of genes encoding TRAP, calci-
tonin receptor (CTR), H+-ATPase, cathepsin K, matrix
metalloproteinase 13 (MMP13), MMP9, tumour necrosis
factor (TNF)α, interleukin (IL)-6, IL-1 or carbonic anhy-
drase 2 (CA2) [12]. Transcription of these genes results
in an increased bone resorption via the attachment of
mature resorptive osteoclasts to the surface of the bone.
Polarization of the osteoclast cytoskeleton, formation of
the “ruffled border” and integrin αVβ3-mediated binding
of the osteoclast to the bone surface, formation of an
acidic microenvironment by the osteoclast and secretion
of enzymes like cathepsin K, TRAP, H+-ATPase or
MMP13 facilitate dissolving of bone mineral and degrad-
ation of bone matrix [12].
During the progression of RA, the inflammatory mi-
lieu of affected joints favours the recruitment and activa-
tion of osteoclasts, leading to a progressive destruction
of joint structures. Among the known inflammatory
modulators, members of the TGF-β super family have
been shown to be important regulators of osteoclasto-
genesis with Smad-mediated signalling being crucial for
inducing osteoclast differentiation. These findings have
opened a new field for exploring inflammatory mecha-
nisms of osteoclast differentiation. Recent studies have
shown that the TGF-β super family members TGF-β1,
myostatin and activin A directly regulate osteoclast dif-
ferentiation through a mechanism dependent on
RANKL–RANK interplay (Fig. 1).
The TGF-β family and their signalling
The TGF-β superfamily is divided into two functional
groups, the TGF-β-like group and the bone morphogenetic
protein (BMP)-like group. The TGF-β-like group consists
of all TGF-βs, activins, nodals and a few growth and differ-
entiation factors (GDFs), whereas the BMP-like group in-
volves BMPs, most GDFs and the anti-Müllerian hormone
(AMH) [24]. These structurally related and secreted poly-
peptides are encoded by 33 genes and characterised by a
signal peptide, a large pro-domain and a C-terminal mature
polypeptide including seven or nine cysteine residues.
These mature polypeptides form disulphide-bonded dimers
that are involved in a high variety of biological activities
such as tissue development and physiology [25].
Only seven type I (also termed activin receptor-like ki-
nases (ALKs)) and five type II receptors are encoded by
the mammalian genome and serve as a receptor reper-
toire for diverse TGF-β-like and BMP-like proteins.
TGF-β and activin proteins bind to the tetrameric cell
surface complex consisting of two transmembrane kin-
ase pairs, type II receptor kinase (TβRII and ActR-II/
ActR-IIB, respectively) and type I receptor kinase (TβRI/
Alk-4 and ActR-I/Alk-2 or ActR-IB/Alk-4, respectively).
The receptor complex is stabilised upon ligand binding
and intracellular signals mediated by Smad proteins are
induced by distinct combinations of type I and type II
receptors depending on the bound ligand [26, 27].
In mammals, eight Smad proteins are known, which are
divided into three subclasses: the receptor-regulated Smads
(R-Smad), the common-mediator Smads (Co-Smads) and
the inhibitory Smads (I-Smads) [26, 28]. It is well known
that TGF-β-like proteins induce their intracellular signals
via phosphorylation of R-Smad2/3 by the type I receptor
kinase while BMPs phosphorylate and activate R-Smad1/5/
8 [27, 29]. Co-Smad-4 can bind to phosphorylated R-
Smad2/3 and the trimeric complex is then translocated into
the nucleus where it binds to high-affinity DNA-binding
transcription factors and conducive Smad-binding DNA se-
quences at regulatory promoter sequences to trigger tran-
scription responses on target genes [25, 26]. I-Smad7 is an
inhibitory regulator of the TGF-β/BMP signalling pathway
which blocks signal transduction upon stably interacting
with the TGF-β-, activin- or BMP-activated type I receptors
[26, 30]. Thereby, TGF-β promotes the transcription of I-
Smad7 as well as promotes the degradation of I-Smad7 by
activation of the Smad3-dependent Smurfs/arcadia-medi-
ated ubiquitin-proteasome degradation pathway [30–32].
Modulation of osteoclastogenesis by TGF-β1
TGF-β1 is a factor with multiple biological properties,
e.g. cell differentiation, proliferation, migration, apop-
tosis, autophagy or production of extracellular matrix
[32–34]. It is expressed in the perichondrium and in
chondrocytes of mouse embryonic cartilage, in the peri-
osteum and in osteocytes in mouse embryonic bones
and by bone marrow cells, chondrocytes, osteoclasts and
in the cartilaginous matrix in adult mice [33, 35, 36]. It
is secreted in a latent form and stored in the extracellu-
lar matrix. Interestingly, opposing effects of TGF-β1
have been described and its function on osteoclastogene-
sis and bone resorption is controversial On the one
hand, TGF-β1 has the ability to increase OPG secretion
by osteoblasts, leading to an inhibition of osteoclast mat-
uration in coculture [14–17]. On the other hand, TGF-
β1 can facilitate bone resorption by recruitment of
osteoclast precursors to the bone environment and pro-
moting osteoclast differentiation in the presence of
RANKL, which can be completely blocked by addition
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of OPG in vitro [16, 33, 37]. Moreover, TGF-β1 can act
dose-dependently on osteoclast differentiation (reviewed
by Janssens et al. [33]) and stimulate osteoclast develop-
ment through enhanced expression of RANK on the sur-
face of monocytic/pre-osteoclastic cells [38].
During osteoclast differentiation, TGF-β binds to its
type II receptor to recruit and phosphorylate type I recep-
tor, leading to the phosphorylation of R-Smad2 and 3. Ac-
tivated p-R-Smad2/3 generates an active Smad complex
by binding to Co-Smad4, which translocates into the nu-
cleus and induces the transcription of several target genes.
In this context, the cooperation of the activated Smad
complex with the co-transcription factor c-Fos is neces-
sary for nuclear translocation and subsequent DNA bind-
ing [39]. In detail, TGF-β enhances the RANKL-mediated
translocation of the activated Smad complex (p-R-Smad2/
3 and p-c-Fos) into the nucleus, followed by c-Fos-
mediated binding of the activated complex to the Nfatc1
gene. This then drives the expression of NFATc1, which is
an essential factor in the regulation of osteoclast differen-
tiation [39]. Furthermore, TRAF6 binds to Smad3 via its
MH2 domain, which is important for the RANKL/RANK
signal transduction [20]. Importantly, inhibition of TGF-β
impairs the formation of the RANKL-induced TRAF6
complex, resulting in impaired intracellular signal trans-
duction through p38 MAPK, JNK or NF-kB signalling
pathways. Finally, TGF-β1 mediates osteoclast survival by
increased ALK5/TβR1 expression and activation of the R-
Smad2/3 complex, which then activates the pro-survival
factor Mcl-1 in mature osteoclasts [40].
The role of TGF-β1 in inflammatory bone
destruction
TGF-β1 is expressed by cells of the synovial lining layer
and macrophages as well as in the vascular endothelium
of synovial tissues of RA patients compared to osteo-
arthritis (OA) and healthy controls [41], and synovial
fluid of RA patients contains TGF-β1, which indicates
that TGF-β1 may be involved in the destruction of the
affected joints [16, 42]. Following this, the role of TGF-
β1 was precisely examined in mouse models of RA but
conflicting results were described for TGF-β1 in murine
models of arthritis [34].
Mice with collagen-induced arthritis (CIA) show a re-
duced occurrence and severity of arthritis when TGF-β1
is intraperitoneally injected at late stages of disease pro-
gression [34, 43] and TGF-β1-transduced mouse bone
marrow-derived mesenchymal stem cells, intraperitone-
ally injected in CIA mice, move to the affected joints
and lead to reduced osteoclastogenesis verified by de-
creased expression of TRAP, cathepsin K or NFATc1 as
well as decreased destruction of the articular cartilage,
synovial hyperplasia, bone erosion and infiltration by in-
flammatory cells [44]. Accordingly, treatment of CIA
mice with an anti-TGF-β1 antibody leads to increased
disease progression [45]. However, others recently
showed that inhibition of TGF-β1 with the specific TGF-
β blocking peptide p17 has only a minor or no effect on
clinical severity, joint inflammation and cartilage de-
struction in the CIA model [46]. In contrast, early stud-
ies showed that the injection of TGF-β1 in healthy knee
joints of mice and rats induced joint inflammation, with
neutrophil recruitment, synovial inflammation and im-
mune cell infiltration [34, 47]. In a model of chronic ero-
sive polyarthritis, anti-TGF-β1 and -2 treatment led to
reduced inflammatory cell accumulation and decreased
tissue degradation and swelling [48].
However, TGF-β1 combined with other cytokines
seems to play a pivotal role in the progression of RA, al-
though rather indirectly in osteoclast-mediated bone de-
struction. In synovial fibroblasts of RA patients, TGF-β1
induces the activity of the transcription factors NF-κB
and AP-1, which are involved in the development of in-
flammation, and enhances the expression of inflamma-
tory mediators such as TNFα, IL-1β, IL-6 and IL-8,
degrading enzymes such as MMP1 and MMP3 as well
as the angiogenic factor VEGF [49, 50]. Additionally,
TGF-β1 has a synergistic effect with TNFα on the ex-
pression of IL-1β in RA synovial fibroblasts [49] and in-
duces the proliferation of synovial fibroblasts through
platelet-derived growth factor (PDGF)-AA and cMyc in-
duction, resulting in a massive synovial hypertrophy in
the affected joints [50].
Moreover, inhibition of the TGF-β1 type I receptor
kinase has a preventive effect on the development of
arthritis in mice [50] and TGF-β1 induces the expression
of transmembrane receptor protein tyrosine phosphatase
κ (RPTPκ), which seems to be involved in cytoskeletal
reorganisation, migration and invasiveness of RA syn-
ovial fibroblasts, promoting fibroblast migration through
dephosphorylation of the tyrosine-protein kinase v-src
avian sarcoma viral oncogene homolog (SRC) [51].
Finally, TGF-β1 promotes the differentiation of
TH17cells, which are recognised as one of the key
players inducing osteoclastogenesis via IL-17A under
inflammatory conditions such as RA [52–56].
TH17 cells differentiate from naïve CD4+ T cells in the
presence of TGF-β1, IL-6 and IL-21 in mice, whereas in
humans IL-6 and IL-1β but not TGF-β1 are essential.
These cytokines are involved in the expression of the
transcription factor RORγt [57–61], which is then re-
quired for de novo TH17 cell differentiation [62–64]
from naïve CD4+ T cells through the upregulation of IL-
7Rα and downregulation of CD27 and IL-2 [65]. IL-23, a
dendritic cell-derived cytokine, is sufficient for IL-17 re-
lease and stabilization of TH17 cells and therefore essen-
tial for their pathogenicity in vivo [66, 67], but early
differentiation occurs independently of IL-23. If IL-23 is
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missing, TH17cells are not terminally differentiated and
will go into apoptosis. Normally, IL-23 promotes the es-
tablishment of a large number of TH17 cells in the
lymph nodes, which then exit the lymph node and mi-
grates to the inflamed tissue, which is also supported by
the local expression of IL-23 [65]. The differentiated
TH17 cells express IL-17A, IL-17 F, IL-21 and IL-22 [68]
and these cells are able to produce RANKL and TNFα,
which are important factors in RA [21, 61, 69, 70]. In
the synovial fluid of patients with RA, levels of IL-17A
are significantly increased in comparison to patients with
OA [71]. IL-17A indirectly leads to the expression of
RANKL by fibroblast-like synoviocytes (FLS) and osteo-
blasts, subsequently leading to the differentiation of
osteoclast precursors into mature osteoclasts [21, 60, 61,
69–71]. Additionally, IL-17A induces the expression of
TNFα, IL-6 and IL-1β by synovial macrophages, which
indirectly leads to the expression of RANKL by osteo-
blasts [61, 72], which in turn promotes osteoclast differ-
entiation as well [21, 55, 56, 64–66]. Furthermore, the
production of IL-6, IL-8, MMP-3 as well as granulocyte
colony-stimulating factor by human FLS is additively/
synergistically induced by IL-17A in combination with
TNFα [73] and the inhibition of IL-17 in hTNFtg mice
leads to delayed bone erosion and cartilage destruction,
whereas inflammation remains unaffected [73, 74].
In summary, TGF-β1 appears to play a pivotal role in
the progression of RA but rather indirectly in combin-
ation with other factors involved in osteoclast-mediated
bone destruction.
Modulation of osteoclastogenesis by myostatin
Myostatin (also known as GDF-8), another member of
the highly conserved TGF-β family, is expressed mainly
in skeletal muscle and acts as an autocrine/paracrine in-
hibitor of skeletal muscle growth [75]. In accordance
with this, deletion of the myostatin gene or a loss of
function mutation leads to muscle hypertrophy and
hyperplasia with an approximate doubling of muscle
mass in mice as well as in other mammals such as dogs,
sheep, cattle or humans [75–78].
However, several findings indicate that myostatin also
plays a role in regulating bone development and that in-
hibition of myostatin diminishes bone resorption and
improves bone formation. Indeed, treatment of mice
with an anti-myostatin decoy receptor (ActRIIB-Fc) re-
sults in a significant increase in bone mass [79] and
myostatin-deficiency leads to increased callus formation
and bone volume in the ossified callus after osteotomy
[80]. Of note, myostatin is expressed during the inflam-
matory phase of fracture healing [81] and it can be sug-
gested, therefore, that the early expression of myostatin
in the callus leads to suppressed recruitment and
proliferation of progenitor cells at the place of fractured
bone [80].
Myostatin is secreted and the latent form of myostatin,
dimerised by disulphide bonds at the C-terminal region,
circulates in the blood. Upon cleavage by the BMP1/Tol-
loid matrix metalloproteinase, the propeptide is released
from the C-terminal domain of myostatin but the active
protein can still be inhibited by its propeptide and other
endogenous inhibitors such as follistatin or follistatin-
related gene (FLRG) [82, 83].
Typically, myostatin transduces intracellular signals by
binding to the heterodimeric receptor complex, com-
posed of the activin type II receptor 2B (ACVR2B) and
the type I receptor ALK4 (known as ACVR1B) or ALK5
(TβR-I), through multiple intracellular signalling cas-
cades, including the SMAD and MAPK pathways [84].
By binding of myostatin to the heterotetrameric receptor
complex, the dormant type I receptor kinase ALK4 and/
or ALK5 is activated, which leads to a subsequent activa-
tion of R-Smad2 and R-Smad3. Co-Smad4 binds to the
activated complex and the whole complex is translocated
into the nucleus, where it activates the transcription of
several genes. The myostatin-induced signalling cascade
is regulated through a negative feedback loop via I-
Smad7, in which I-Smad7 inhibits the myostatin promo-
tor activity and myostatin transcription via cooperation
with Smurf1 [83, 85].
The role of myostatin in inflammatory bone
destruction
A recent study demonstrated that myostatin is signifi-
cantly involved in inflammatory bone loss in RA by dir-
ectly promoting osteoclast formation. Myostatin is
expressed in synovial tisssues of RA patients in contrast
to those of OA patients, indicating that myostatin is up-
regulated in synovial-like fibroblasts during the inflam-
matory progression of RA in humans. Additionally,
myostatin is expressed in synovial membranes of human
TNFa transgenic (hTNFtg) compared to wild-type mice
[86]. These mice spontaneously develop a TNFα-
dependent chronic destructive arthritis. Overexpression
of TNFα in mice is sufficient to trigger full-blown de-
structive arthritis with synovial inflammation, cartilage
damage and bone destruction [87].
Moreover, the lack or pharmacological inhibition of
myostatin in hTNFtg mice led to reduced severity of RA
and decreased bone erosion in the joints associated with
a decreased number of mature osteoclasts as well as a
significantly diminished inflammatory response [86].
Interestingly, myostatin by itself is not able to induce
the formation of mature osteoclasts from bone marrow-
derived macrophages (BMMs), but is able to enhance
the ability of osteoclast precursors to differentiate into
mature osteoclasts in a RANKL/M-CSF-dependent
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manner. The treatment of BMMs with myostatin, M-
CSF and RANKL leads to the establishment of very large
osteoclasts with a huge cytoplasmic compartment and a
large number of nuclei in comparison to mature osteo-
clasts cultivated under normal conditions (M-CSF,
RANKL). Besides a paracrine role, myostatin has an add-
itionally autocrine role as demonstrated by decreased
RANKL-induced osteoclastogenesis by myostatin-
deficient cells and lower osteoclast numbers in the tibea
of myostatin-deficient mice [86].
During osteoclastogenesis, myostatin binds to its hetero-
dimeric receptor complex on the surface of precursor and
mature osteoclasts and subsequent activation of ALK4 or
ALK5 leads to the recruitment of R-Smad2. R-Smad2 is ac-
tivated via phosphorylation (p-R-Smad2) and binds to
NFATc1. These complexes are then translocated into the
nucleus of precursor osteoclasts to enhance expression of
several osteoclast-specific target genes. In detail, myostatin
enhances the RANKL-dependent expression of integrin
αvβ3, DC-STAMP and calcitonin receptor as well as
NFATc1 itself. However, myostatin has no effect on the ac-
tivation of the MAPKs p38α, c-Jun N-terminal kinase
(JNK) and the extracellular signal-regulated kinase 1/2
(ERK1/2) nor the NF-κB pathway during osteoclast differ-
entiation. However, apart from a decrease in osteoclast de-
velopment and bone destruction, a strong reduction in
inflammation can be observed in myostatin-deficient arth-
ritic mice [86]. This in vivo observation is of great import-
ance since under inflammatory conditions there is local
and/or systemic alteration in the levels of proinflammatory
cytokines and growth factors that are known to stimulate
bone resorption in vitro and in vivo [9, 10]. Thus, beside a
direct effect on osteoclast development, myostatin appears
to additionally modulate joint inflammation.
Modulation of osteoclastogenesis by activin A
Activin A, a homodimer, is structurally composed of two
βA subunits (βAβA) connected with disulphide bonds.
Activin A acts as an autocrine as well as paracrine regu-
lator and is expressed in a number of tissues such as
ovary, pituitary gland, brain, placenta and bone marrow.
In the bone marrow, activin A is most likely expressed
by bone marrow macrophages, monocytes, osteoblasts,
osteoclasts and endothelial cells [88–91].
Activin A acts as a powerful co-factor of the M-CSF/
RANKL-induced differentiation of pre-osteoclasts and in-
hibition of activin A by its soluble receptor can abrogate
osteoclast differentiation, indicating that activin A might be
an essential factor for osteoclast differentiation [89, 92, 93].
Interestingly, activin A also stimulates osteoblast differenti-
ation from murine bone marrow and promotes fracture
healing in a rodent facture model, suggesting that activin A
is involved in both bone formation and bone resorption
during bone remodelling [94, 95]. Indeed, inbibition of
activin A suppressed osteoclastic bone resorption, e.g. bone
lesions and metastasis, and stimulated osteoblastic bone
formation in mouse models of myeloma and breast cancer,
respectively [96, 97]. In contrast, it has also been shown
that activin A inhibits the differentiation of osteoblast pre-
cursors of rat calvaria [88]. Most interestingly, autocrine
activin A affects the late phase of osteoblast differentiation,
in which activin inhibits bone matrix formation and min-
eralisation, indicating that activin A might control bone
quality during remodelling as well as pathological mineral-
isation [98].
Similar to myostatin, activin A signals through a com-
bination of ACVR2B or ACVR2A and ALK4/7 recep-
tors, thereby activating the Smad, NF-κB, ERK and p38
signalling pathway [92, 99]. Activin A has a stimulatory
effect on RANK-mediated osteoclastogenesis via the ac-
tivation of the IkBα/NF-κB pathway. This in turn in-
duces the transcription of RANK by osteoclast precursor
cells, leading to a higher susceptibility to RANKL [93].
In contrast to activin A, myostatin has the ability to acti-
vate R-Smad-2 but did not activate MAPK or NF-κB in
osteoclasts, indicating that, despite using common re-
ceptors, they can activate different pathways [86, 88].
Recently, a conflicting report on osteoclast formation
by activin A has been published suggesting that activin
A acts as a local regulator during osteoclast development
at multiple stages of osteoclast maturation by having a
dominant negative effect on RANKL-stimulated osteo-
clast motility as well as osteoclast lifespan [100]. Inter-
estingly, by testing whole bone marrow cultures or
enriched osteoclast progenitor cultures they found en-
hanced RANKL-mediated osteoclast development simi-
lar to what has been described previously [89, 92, 93].
However, activin A had no effect on stroma-free BMMs
stimulated with M-CSF and RANKL, suggesting that the
stimulatory effect of activin A on osteoclastogenesis is
mediated by other non-macrophage like cells in the
bone marrow. From their study, they claim, that activin
A has no pro-osteoclastogenic effect on stroma-free
BMMs, whereas activin A acts as a negative regulator of
RANKL-induced osteoclast motility by activation of R-
Smad2 and Akt1, which leads to activation of IκBα, a
negative regulator of the NF-κB pathway [100].
In contrast to the inhibition of osteoblastic bone
formation in myeloma and breast cancer mouse
models by activin A [96, 97], it has been demon-
strated very recently that, in fibrodysplasia ossificans
progressive (FOP), a constitutively activating muta-
tion (R206H) of the bone morphogenetic protein
type 1 receptor activin-like kinase 2 (ACVR1/ALK2)
leads to an extensive ossification of skeletal muscle,
fascia, ligaments and tendons. Due to this single nu-
cleotide mutation at the position 617G-A, activin A
could activate the mutated type I receptor ACVR1/
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AlK2, which normally can only be activated by BMPs
[101–103]. During FOP progression, the differenti-
ation of ACVR1(R206H)-expressing cells towards the
osteoblast linage is enhanced through BMP-induced
hetero-oligomeric type-II/ACVR1(R206H) complex hy-
peractivation [103]. Hatsell et al. [101] as well as Hino et
al. [102] demonstrated that activin A binds to the mutated
ACVR1(R206H) receptor and induces the phosphoryl-
ation of SMAD 1/5/8. Interestingly, activin A normally
binds to ACVR1/ALK-2, acting as an antagonist by block-
ing BMP binding to the receptor [103]. Hatsell et al. [101]
used a specific conditional-on knock-in ACVR1R206H
mouse and showed enhanced heterotopic ossification in-
duced by activin A which could be inhibited by the use of
activin A neutralizing antibodies [101, 103]. Accordingly,
implantation of ACVR1(R206H)-transfected myoblastic
C2C12 cells in nude mice caused heterotopic ossification
in muscle tissue [104]. Together, these data indicate not
only an important crosstalk between myogenesis and
osteogenesis but also point to an important role for activin
A in bone remodelling. However, the increased formation
of osteoclasts in the muscle tissue after transplantation of
transfected myoblastic C2C12 cells was not dependent on
activin A but on TGF-β1 [104].
Nevertheless, the induction of activin A in many
cell types by pro-inflammatory cytokines in response
to injury and inflammation makes a crosstalk also be-
tween inflammation and osteogenesis most likely.
The role of activin A in inflammatory bone
destruction
Activin A is expressed in FLS of the lining and sublining
layers and by macrophages in the active RA synovium.
Expression of activin A by FLS is stimulated by pro-
inflammatory cytokines such as TNF-α, IL-1β and TGF-
β; IL-1β appears to be the strongest inducer of activin A
secretion by FLS [90]. Moreover, activin A is expressed
in α-smooth muscle actin (αSMA) high-expressing FLS
from high-inflammatory synovial tissues of RA patients,
further confirming an important role in the pathogenesis
of RA [105].
Additionally, higher levels of activin A in the synovial
fluid of RA patients compared to systemic lupus erythe-
matosus, OA and control patients could be observed
[106]. Interestingly, high levels of activin A present in the
synovial fluid of RA patients were generated by
granulocyte-macrophage colony stimulating factor (GM-
CSF)-dependent differentiated pro-inflammatory macro-
phages (M1) [91, 107]. Thus, activin A from the synovial
fluid of RA patients contributes to the polarisation to-
wards pro-inflammatory GM-CSF-mediated M1 macro-
phages, inhibits lipopolysaccharide-mediated IL-10
secretion by M2 macrophages and decreases the expres-
sion of anti-inflammatory M2 (M-CSF)-dependent
markers in monocytes and macrophages [91, 107]. This
supports the notion that activation and polarization of
synovial fluid macrophages by activin A are important
processes for pathogenic progression and severity of RA
in the affected joints [91].
In fact, it has been shown that activin A can act as a
pro- or anti-inflammatory mediator, which is dependent
on its concentration at the site of inflammation. High acti-
vin A levels promote anti-inflammatory processes,
whereas low levels exert most likely pro-inflammatory ef-
fects, which could be associated with the activation of
pro- or anti-inflammatory macrophages (reviewed by
Dong and He [108]).
In this regard, enhanced production of activin A could
be observed after stimulation of monocytes derived from
human peripheral blood with synovial fluid of RA pa-
tients and macrophages from the synovial fluid of RA
patients showed a higher expression of p-R-Smad2 in
comparison to pro-inflammatory or anti-inflammatory
macrophages derived from peripheral blood mono-
nuclear cells [91].
Besides a direct role on macrophages and osteoclasts,
activin A appears to have an additionally indirect role in
bone destruction in RA. Of interest, activin A has the cap-
ability to induce the proliferation of synovial fibroblasts,
suggesting a role for it in the formation of an invasive pan-
nus that destroys articular cartilage and bone in RA joints
[90]. Indeed, many studies revealed a higher expression of
RANKL in synovial tissues and synovial fibroblasts from
RA compared to OA patients and exclusively co-cultures
with synovial fibroblasts from patients with RA promote
osteoclast development in vitro, indicating that upregula-
tion of RANKL in activated synovial fibroblasts may facili-
tate the differentiation of osteoclasts [109, 110]. Thus,
enhanced formation of pannus tissue by activin A, associ-
ated with increased levels of RANKL, may be responsible
for increased bone destruction in RA.
Future perspectives on the treatment of RA
The present data suggest that the inhibition of certain
members of the TGF-β superfamily and their down-
stream, Smad-dependent signalling pathways may be of
benefit for RA and constitute novel, so far incompletely
explored treatment options. This notion is based on a
number of observations as outlined in this review. First,
the data indicate that particularly the inhibition of
Smad-2 activation may exert effects that are distinct
from other signalling pathways and thus provide add-
itional benefit over existing and recently explored target-
ing options such as MAPK or JAK/STAT inhibition.
Second, it appears that, in addition to their classic roles,
e.g. of myostatin on muscle biology, Smads, and again
specifically Smad-2, are involved in the shuttling and ac-
tivation of other transcription factors (e.g. c-fos,
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NFATc1) that control one key aspect of RA pathogen-
esis, namely bone destruction. Inhibition of these path-
ways may, therefore, combine strong anti-resorptive
effects with benefits in other, more systemic disease
manifestations, such as muscle weakness or inflamma-
tion. Certainly, a number of important questions remain
to be answered. These relate both to the exact mecha-
nisms by which the activation of Smads and their up-
stream activating receptors regulate and link the
different disease mechanism of RA and also to required
dosages and potential unwanted effects. Nonetheless, the
current evidence not only warrants further exploration
of the underlying signalling pathways and their relevance
for RA but also the initiation of furher (pre-)clinical
steps towards the use of existing compounds such as
myostatin inhibitors.
Conclusions
RA is a chronic inflammatory disease that is characterised
by progressive destruction of the joints, mainly caused by
osteoclastic bone resorption. Osteoclasts differentiate
from hematopoietic precursors or tissue-resident macro-
phages by RANKL, a key factor of osteclast differentiation,
expressed by synovial fibroblasts and activated T cells and
regulated by pro-inflammatory cytokines which are highly
expressed in the inflamed pannus tissue as well. Although
RANKL is essential for osteoclast formation, other factors,
which additionally are abundant in the synovial membrane
or bone of patients with RA, are able to potently stimulate
osteoclast development. In this regard, TGF-β1, myostatin
and activin A, all members of the TGF-β family, enhance
RANKL-induced osteoclast formation, suggesting an im-
portant role of Smad signalling in the regulation of osteo-
clast differentiation and inflammatory bone loss. The
identification of additional players in inflammatory bone
resorption may contribute significantly to the discovery of
new and better drugs for the treatment of joint destruc-
tion in arthritis.
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